Bausch + Lomb Discontinues BL1107 Eye Drops for Glaucoma After Phase 2 Miss
The company will discontinue the topical program but continue advancing a sustained-release implant for geographic atrophy.
/ 1648 items
#XY↓
Steel Partners Launches $16.75 Takeover Bid for InMode, Surpassing CEO-Backed Offer
The firm criticizes CEO Moshe Mizrahy and urges the board to act.
FDA Clears Fate Therapeutics’ Dual-Target CAR-T FT839 for Autoimmune Diseases
Following positive FT819 data in systemic sclerosis, the company now targets multiple autoimmune indications.
Oppenheimer Initiates Outperform Coverage on Connect Biopharma with $8 Target, Implies 3.6x Upside
Rademikibart’s rapid action in acute asthma & COPD positions it for major upside ahead of Phase 2 readouts.
Qiagen Draws Early Takeover Interest from EQT, Advent, and KKR
No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation.
Wainua Trial Setback Sends Ionis Plunging and Drags Down AstraZeneca
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.